Veeva Systems has announced that Neuraxpharm will use Veeva Vault QualityDocs and Veeva Vault Training to advance its quality operations, which will help Neuraxpharm achieve greater oversight and inspection readiness while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).
Neuraxpharm agrees on divestment of inhalation API specialist Inke to Keensight
Neuraxpharm`s Briumvi (ublituximab) Receives Approval in Europe
EC revokes all centrally granted generic marketing permissions for DMF
Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones Neuraxpharm™s dedicated neurology focus and established European presence makes them an attractive...
BARCELONA, Spain and DÜSSELDORF, Germany, July 11, 2023 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the establishment of affiliates in Brazil and Mexico, the two largest pharmaceutical markets in Latin America1, as first steps in its expansion outside of Europe.
Neuraxpharm announces closing of acquisition of established products from Sanofi
BRUSSELS and DÜSSELDORF, Germany, Jan. 24, 2023 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence in Benelux as it continues its expansion pathway in Europe.
NAARDEN, Netherlands and DÜSSELDORF, Germany, Dec. 7, 2022 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Netherlands. The expansion into the Dutch market allows Neuraxpharm to continue on its pathway to become the number one CNS specialist in Europe.
Minoryx Therapeutics and the Neuraxpharm Group enter into a license agreement for the European rights to leriglitazone, which is currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).